Shanghai Junshi Biosciences688180.SHValuation Analysis

As of Oct 19, 2026, Shanghai Junshi Biosciences (688180.SH) trades at a negative P/E (-69.80x, due to a recent net loss), P/B of 5.20x, P/S of 9.07x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 30th percentile over the trailing 10Y window (vs. 47th percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 87th percentile within its industry and the 82nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shanghai Junshi Biosciences operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.